Editorial Comment
Inhibiting the Inhibitor Victor J. Marder, MD L ike any hemostatic system worth its salt, fibri- nolysis is governed by competing influences, some of which promote lysis whereas others resist lysis. Reduced to the bare minimum, tissuetype plasminogen activator (t-PA) is profibrinolytic, whereas plasminogen activator inhibitor-1 (PAI-1) neutralizes t-PA and is therefore antifibrinolytic. Simple enough, but now Levi et all ask whether PAI-1 retards the physiological fibrinolytic response to a thrombus, and they test the hypothesis by blocking PAI-1 action with a monoclonal antibody: The inhibitor is inhibited. The results show that incorporation of the anti-PAI-1 antibody into an experimental (human) clot in the rabbit jugular vein accelerates physiological thrombolysis, presumably by neutralizing the effect of platelet PAI-1 to retard thrombolysis. The monoclonal antibody also prevents thrombus extension by potentiating both the physiological t-PA response and the response to therapeutic t-PA infusion.
The data have relevance for understanding the physiology of fibrinolysis, and they cement our understanding of the role of PAI-1. However, a cautionary note is indicated because the antibody is active only if it has been incorporated into the forming thrombus. This limits the applicability of such an approach and virtually precludes its use in acute myocardial infarction, unless the antibody (or some portion thereof, or a small peptide mimicking its inhibitory action) could somehow enter the formed thrombus and attach to the fibrin-bound PAI-1. The approach could be applicable for prophylactic use, however, perhaps in preventing thrombotic reocclu- 
